HC Wainwright Analysts Cut Earnings Estimates for MLTX

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities researchers at HC Wainwright lowered their Q3 2025 earnings per share estimates for MoonLake Immunotherapeutics in a research report issued on Monday, August 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.96) per share for the quarter, down from their prior estimate of ($0.79). The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.37) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.95) EPS, Q4 2026 earnings at ($1.02) EPS and FY2026 earnings at ($3.64) EPS.

Other analysts have also recently issued research reports about the company. Wedbush restated an “outperform” rating and issued a $80.00 price target (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. The Goldman Sachs Group upped their price target on MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the stock a “buy” rating in a research report on Wednesday, August 6th. Royal Bank Of Canada restated an “outperform” rating and issued a $67.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 3rd. Rothschild & Co Redburn started coverage on MoonLake Immunotherapeutics in a research report on Monday, July 28th. They issued a “neutral” rating and a $65.00 price target for the company. Finally, Wolfe Research upgraded MoonLake Immunotherapeutics from a “peer perform” rating to an “outperform” rating and set a $61.00 price target for the company in a research report on Monday, May 19th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $74.43.

MoonLake Immunotherapeutics Stock Performance

Shares of MLTX opened at $54.88 on Thursday. The company has a quick ratio of 16.65, a current ratio of 16.65 and a debt-to-equity ratio of 0.21. The business has a 50-day simple moving average of $49.45 and a two-hundred day simple moving average of $43.40. The stock has a market cap of $3.51 billion, a price-to-earnings ratio of -19.74 and a beta of 1.27. MoonLake Immunotherapeutics has a 52 week low of $31.42 and a 52 week high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.14). During the same quarter in the prior year, the firm posted ($0.39) earnings per share.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Hedge funds have recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of MoonLake Immunotherapeutics by 17.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,236 shares of the company’s stock worth $2,287,000 after acquiring an additional 6,422 shares during the period. Victory Capital Management Inc. boosted its stake in MoonLake Immunotherapeutics by 44.6% during the first quarter. Victory Capital Management Inc. now owns 258,150 shares of the company’s stock valued at $10,086,000 after buying an additional 79,649 shares during the last quarter. New York State Common Retirement Fund bought a new position in MoonLake Immunotherapeutics during the first quarter valued at approximately $273,000. Rice Hall James & Associates LLC boosted its stake in MoonLake Immunotherapeutics by 23.7% during the first quarter. Rice Hall James & Associates LLC now owns 137,516 shares of the company’s stock valued at $5,373,000 after buying an additional 26,383 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in MoonLake Immunotherapeutics during the fourth quarter valued at approximately $3,485,000. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.